A day before its Q1 earnings report, Duke Energy (NYSE: DUK ) announced today that it will suspend any plans to apply for new nuclear units on its North Carolina Harris site.
The construction and operating applications were originally submitted by Progress Energy in 2008, and fell under Duke's domain after a July 2012 merger between the two utilities.
Although Duke Energy President Dhiaa Jamil noted in a statement that the site is "well suited for new nuclear generation and has not been eliminated from our long-term consideration," slower power growth has put any new construction plans on the back burner. According to Jamil, "Our most recent forecast indicates two additional nuclear units at Harris will not be needed in the next 15 years."
Instead, the company will continue to focus on its $9 billion fleet modernization efforts, which brought three power plants (two natural gas combined-cycle and one "clean coal�") online in 2012, and should add another combined-cycle facility later this year.
Top Logistics Companies For 2015: National Health Investors Inc. (NHI)
National Health Investors, Inc., a real estate investment trust (REIT), invests in health care properties, primarily in the long-term care industry in the United States. As of December 31, 2008, it had investments in real estate assets and mortgage notes receivable investments in 123 health care facilities consisting of 83 long-term care facilities, 1 acute care hospital, 4 medical office buildings, 14 assisted living facilities, 4 retirement centers, and 17 residential projects for the developmentally disabled in 17 states. The company has elected to be treated as a REIT for federal income tax purposes and would not be subject to federal income tax, if it distributes at least 90% of its REIT taxable income to its shareholders. National Health Investors, Inc. was founded in 1991 and is based in Murfreesboro, Tennessee.
Advisors' Opinion:- [By Marc Bastow]
Long-term care and senior housing real estate investment trust National Health Investors (NHI) raised its quarterly dividend 6.2% to 77 cents per share, payable on May 9 to shareholders of record as of Mar. 31. NHI stock has the second-highest yield on this week’s list of dividend stocks increasing payouts.
NHI Dividend Yield: 4.88% - [By Lauren Pollock]
National Health Investors Inc.(NHI) signed an agreement to acquire 25 independent-living facilities from Holiday Retirement Corp. affiliates for $491 million. The health-care focused real-estate investment trust also unveiled plans to offer 4.5 million shares of its stock to help fund the pending deal.
- [By Jonas Elmerraji]
After performing pretty poorly in the last year, $2 billion healthcare property owner National Health Investors (NHI) has gone from laggard to leader in 2014. Since the start of the year, NHI has moved more than 11% higher, stomping the S&P 500's performance by comparison. And now, NHI looks well positioned for another leg up...
NHI is forming a "rounding bottom" pattern, a basic classic setup that looks exactly like it sounds: it's identified by a curved support level below shares and a horizontal resistance level to the top side. That rounded support line indicates a gradual shift in control from sellers to buyers -- and resistance at $63 is the price level to watch from here.
Why all the significance at $63? It all comes down to buyers and sellers. Price patterns are a good quick way to identify what's going on in the price action, but they're not the reason a stock is tradable. Instead, the "why" comes down to basic supply and demand for NHI's stock.
The $63 resistance level is a price where there has been an excess of supply of shares; in other words, it's a spot where sellers have previously been more eager to step in and take gains than buyers have been to buy. That's what makes a breakout above $63 so significant -- the move means that buyers are finally strong enough to absorb all of the excess supply above that price level.
Top Industrial Disributor Companies To Buy Right Now: Atlantic Power Corp (AT)
Atlantic Power Corporation (Atlantic Power) owns and operates a fleet of power generation and infrastructure assets in the United States and Canada. The Company�� power generation projects sell electricity to utilities and industrial customers under long-term power purchase agreements. During the year ended December 31, 2011, its power generation projects in operation had an aggregate gross electric generation capacity of approximately 3,397 megawatts in which its ownership interest was approximately 2,140 megawatts. The Company operates in five segments: Northeast, Southeast, Northwest, Southwest and Un-allocated Corporate. As of December 31, 2011, its portfolio consisted of interests in 31 operational power generation projects across 11 states in the United States and two provinces in Canada, and a 53 megawatts biomass project under construction in Georgia and a 500-kilovolt 84-mile electric transmission line. On December 31, 2012, the Company acquired Ridgeline Energy Holdings, Inc. Advisors' Opinion:- [By Markus Aarnio]
Emera's competitors include Northland Power (NPIFF.PK), Fortis (FRTSF.PK), and Atlantic Power (AT). Northland Power has seen insider buying in August and has a dividend yield of 7.6%. Fortis has seen both insider buying and insider selling in August. Fortis has a dividend yield of 4.1%. Atlantic Power saw insider buying last time in April. Atlantic Power has a dividend yield of 9.4%.
- [By Justin Loiseau]
But dividends can be a major drain, as evidenced by Exelon's (NYSE: EXC ) and Atlantic Power's (NYSE: AT ) recent dividend haircuts. Exelon cut its dividend 40%, and Mr. Market has heavily rewarded its decision with a soaring stock price. Atlantic's decision may have been too little, too late, as the utility's 66% dividend division has been accompanied by a steep decline in share prices.
- [By Selena Maranjian]
A good dividend investor needs to remember that dividend amounts are not set in stone. Companies do try hard to not reduce or eliminate them, but that happens sometimes. Recently, for example, both Atlantic Power (NYSE: AT ) and Exelon (NYSE: EXC ) reduced their dividends -- by 65% and 40%, respectively. Atlantic had been yielding 10%, and Exelon 6.8%. Atlantic still sports a hefty yield, but that's because its stock has fallen some 62% over the past three months amid poor results and worries over lawsuits. Exelon, a nuclear-power specialist, is viewed more favorably, and has been investing in renewable energy, as well. Still, some think it could be a while before its also-depressed stock turns around.
Top Industrial Disributor Companies To Buy Right Now: Toll Brothers Inc.(TOL)
Toll Brothers, Inc., together with its subsidiaries, designs, builds, markets, and arranges finance for single-family detached and attached homes in luxury residential communities. It is also involved in building or converting existing rental apartment buildings into high-, mid-, and low-rise luxury homes. In addition, the company develops, owns, and operates golf courses and country clubs associated with various planned communities, as well as individual communities. It serves move-up, empty-nester, active-adult, age-qualified, and second-home buyers in 19 states in the United States. Toll Brothers, Inc. was founded in 1967 and is headquartered in Horsham, Pennsylvania.
Advisors' Opinion:- [By John Maxfield]
The latter was on display last week when Toll Brothers (NYSE: TOL ) reported earnings for its fiscal second quarter ended April 30. Aside from the fact that the nation's largest luxury homebuilder notched higher revenue and net income, the most tangible evidence of progress was in the number of units sold or put under contract. Compared with last year, the company saw its net signed-contract count increase by 36%. And over the same time period, the price of each contract advanced from $631,000 to $678,000.
- [By Jake L'Ecuyer]
Top Headline
Toll Brothers (NYSE: TOL) reported a better-than-expected fourth-quarter profit. Toll Brothers' quarterly profit declined to $94.9 million, or $0.54 per share, versus a year-ago profit of $411.4 million, or $2.35 per share. - [By Sinisa Persich]
Toll Brothers Inc. (TOL) �has been consolidating its big run from 32.50 through resistance at 35.00 and up to near 37.00 in mid-December, flagging for the last eight weeks, and making higher lows. A move above 37.19 would break the stock out of its current flag formation.
Top Industrial Disributor Companies To Buy Right Now: Artek Exploration Ltd (ARKXF.PK)
Artek Exploration Ltd. (Artek) is a junior oil and gas company engaged in the exploration for, and the acquisition, development and production of, oil and natural gas reserves in western Canada. Artek's principal properties include Peace River Arch, Alberta; Deep Basin, Alberta and British Columbia; Inga/Fireweed, British Columbia, and Central Alberta. During the year ended December 31, 2011, the Company drilled six gross (3.7 net) wells, including two gross (1.6 net) oil wells and four gross (2.1 net) natural gas wells. On June 20, 2012, it had drilled and completed its second of a seven horizontal well program (60% working interest) at its Doig natural gas and condensate pool in the Inga area of British Columbia. On January 1, 2012, the Company divested 33% of its non-operated oil and gas assets in the Leduc Woodbend area. In August 2013, the Company announced that it has completed the acquisition of Fireweed asset. Advisors' Opinion:- [By Value Digger]
As peers, I selected Artek Exploration (ARKXF.PK), RMP Energy (OEXFF.PK), Synergy Resources (SYRG) and Magnum Hunter Resources (MHR). The first two firms trade also on the main Toronto board under the tickers RTK.TO and RMP.TO respectively. These peers comply with the following criteria:
Top Industrial Disributor Companies To Buy Right Now: Amedica Corp (AMDA)
Amedica Corporation (Amedica), incorporate on December 10, 1996, is a commercial biomaterial company focused on using its silicon nitride technology platform to develop, manufacture and sell a broad range of medical devices. The Company market spinal fusion products and are developing products for use in total hip and knee joint replacements. The Company markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States and Europe for use in the cervical and thoracolumbar areas of the spine. In addition to its silicon nitride-based spinal fusion products, it markets a complementary line of non-silicon nitride spinal fusion products which allows us to provide surgeons and hospitals with a broader range of products. These products include three lines of spinal fusion devices and five types of orthobiologics, which are used by surgeons to help promote bone growth and fusion in spinal fusion procedures.
The Company�� non-silicon nitride products have accounted for approximately 70% or more of its product revenues for the years ended December 31, 2013. The Company�� also incorporating its silicon nitride technology into components for use in total hip and knee replacement product. Biomaterials are synthetic or natural biocompatible materials that are used in virtually every medical specialty to improve or preserve body functionality.
Advisors' Opinion:- [By James E. Brumley]
Stocks as a whole haven't gotten the new year off on the best foot, but that's not to say every equity out there is in trouble. Indeed, some small cap stocks may actually be doing well - and poised to do well for a while - specifically because larger companies are seeing their stocks struggle. To that end, traders looking for a bullish bright spot to start the new year may want to take a closer look at Amedica Corporation (NASDAQ:AMDA), Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), and Aethlon Medical, Inc. (OTCMKTS:AEMD).
Top Industrial Disributor Companies To Buy Right Now: TESARO Inc (TSRO)
TESARO, Inc. (TESARO), incorporated in March 2010, is a development-stage, oncology-focused biopharmaceutical company for cancer patients. The Company focuses on rolapitant and TSR-011 product. The Company�� marketed products and product candidates in development treat cancer through non-specific damage to cellular components or alter cell metabolism or internal repair mechanisms to the demise of cancer cells.
Rolapitant
Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting (CINV). It is in Phase III clinical trials. CINV, if not prevented by prophylaxis, has the potential to afflict up to 90% or more of cancer patients undergoing chemotherapy, depending upon the type of chemotherapy administered the dosing schedule of the chemotherapy, and the patients' age and gender, among other predisposing factors. Prolonged nausea and vomiting may result in unwanted weight loss, dehydration and malnutrition, as well as hospitalization. The Company has in-licensed the rights to rolapitant from OPKO Health, Inc.
TSR-011
TSR-011 is an orally available ALK inhibitor in preclinical development. ALK is known to be involved in certain types of cancers, including subsets of NSCLC, neuroblastoma and lymphoma. For patients in these subsets, the ALK gene is fused to an activating partner or contains point mutations, resulting in constitutive activation of ALK and the growth of cancer cells and tumor development. Inhibition of ALK in these cancer cells results in cell death and tumor growth inhibition or regression. In August 2011, the United States Food and Drug Administration approved the first ALK inhibitor, developed by Pfizer Inc., Xalkori (crizotinib), which was approved for the treatment of patients with locally advanced or metastatic NSCLC that are ALK positive.
The Company competes with GlaxoSmithKline plc, Roche Holding Ltd! . and Sanofi S.A.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading UP
Tesaro (NASDAQ: TSRO) shares shot up 18.28 percent to $28.40 after the company reported successful primary and secondary endpoints in final Phase 3 trial for rolapitant.
No comments:
Post a Comment